Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly
Read more at CNBC
-
Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure
Novo Nordisk's hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt after a series of trial results have left investors feeling unsatisfied.CNBC - 1d -
Novo Nordisk cuts Wegovy prices, following similar move by Zepbound-maker Eli Lilly
Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insuranceABC News - Mar. 5 -
Novo Nordisk shares fall on latest trial results for new obesity drug
Participants with type 2 diabetes had an average weight loss of 15.7 per cent after 68 weeks on CagriSemaFinancial Times - Mar. 10 -
Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug
Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.CNBC - Mar. 10 -
Healthy Returns: Wegovy is linked to an increased risk of hair loss, study suggests
Novo Nordisk's weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom received a warning letter from FDA.CNBC - Mar. 11 -
Zepbound copycats remain online despite FDA ban
Copycat versions of Eli Lilly's diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They're still available on some websites.CNBC - 3d -
Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
The trial results are critical, as it brings Eli Lilly's pill one step closer to becoming a new, needle-free alternative for weight loss and diabetes.CNBC - 1d -
Roche shares pop 5% on $5.3 billion obesity drug deal with Zealand Pharma
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma's obesity drug candidate.CNBC - Mar. 12 -
Roche takes big step in weight-loss field with $5.3 billion deal. Novo Nordisk shares fall.
Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to Zealand Pharma in a licensing and development deal.MarketWatch - Mar. 12
More from CNBC
-
Chinese EV giant BYD outpaces Tesla with annual sales of more than $100 billion
China's BYD reported annual revenue of 777 billion yuan ($107 billion) for 2024, leapfrogging Tesla as competition between the two EV rivals heats up.CNBC - 15h -
Recession is coming before end of 2025, generally 'pessimistic' corporate CFOs say: CNBC survey
The US economy will enter a recession in 2025, with Trump's tariffs leading top corporate CFOs to 'pessimism' and less spending, according to a CNBC survey.CNBC - 15h -
U.S. blacklists over 50 Chinese companies in bid to curb Beijing's AI, chip capabilities
The export restrictions come at a time when tensions between Washington and Beijing have been rising with the Trump administration ratcheting up tariffs against China.CNBC - 1h -
Amazon is testing shopping, health assistants as it pushes deeper into generative AI
With CEO Andy Jassy pushing employees to build AI apps across the company, Amazon is testing new shopping and health assistants.CNBC - 2h -
With 23andMe entering bankruptcy, here's how to delete your genetic data
Now that 23andMe has filed for bankruptcy, another company could take control of its genetic database.CNBC - 6h
More in Business
-
U.S. blacklists over 50 Chinese companies in bid to curb Beijing's AI, chip capabilities
The export restrictions come at a time when tensions between Washington and Beijing have been rising with the Trump administration ratcheting up tariffs against China.CNBC - 1h -
Rising debt and spending demands squeeze Britain’s finances
UK gross government debt rose from 85.7% of GDP in 2019 to 101.8% in 2024Financial Times - 1h -
Inside Russia’s Gazprom: can the ailing energy giant be revived?
The gas and oil company is struggling to recover from record losses after Putin’s full-scale invasion of Ukraine destroyed its business modelFinancial Times - 1h -
Top Fed official says market angst over inflation would be ‘red flag’
Austan Goolsbee’s warning comes after key survey shows consumers expect soaring price growthFinancial Times - 1h -
Fidelity plans to launch stablecoin in digital assets push
Asset manager is in advanced stages of testing token as the Trump administration prepares to overhaul crypto oversightFinancial Times - 1h